Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Больной артериальной гипертензией и метаболическим синдромом: какой b-адреноблокатор выбрать?
Больной артериальной гипертензией и метаболическим синдромом: какой b-адреноблокатор выбрать?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Метаболический синдром. Под ред. Г.Е.Ройтберга, М.: МЕДпресс-информ, 2007.
2. Ройтберг Г.Е., Дорож Ж.В., Курукшина О.В. Роль адипокинов в прогрессировании метаболических нарушений у пациентов без ожирения с унсулинорезистентностью. Профилактическая медицина. 2010; 5: 23–6.
3. Boden-Albala B, Suzuki T, Hirata K et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J 2008; 156 (2): 405–10.
4. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86 (2): 713–8.
5. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–12.
6. Sharma AM, Pischon T, Hardt S et al. Hypothesis: beta-adrenergic receptor blockers and weight gain:systematic analysis. Hypertension 2001; 37: 250–4.
7. Elliot WJ, Meyer PM. Incident diabet s in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 207–10.
8 Kovacić D, Marinsek M, Gobec L et al. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008; 97 (1): 24–31.
9. Celik T, Iyisoy A et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24 (3): 591–6.
10. Wofford MR, Fnderson DC Jr, Brown CA et al. Antihypertenzive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001; 14: 694–8.
11. Schmieder RE, Gatzka C, Schachinger H et al. Obesity as a determinant for response to antihypertensive treatment. Br Med J 1993; 307: 537–40.
12. Ladage D, Brixius K, Hoyer H et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 2006; 33: 720–4.
13. Rizos E, Bairaktari E, Kostoula A et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8: 127–34.
14. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591–6.
15. Manrique C et al. Nebivolol improves insulin sensitivity in the TGR (Ren2) 27 rat. Metabolism 2011; 60 (12): 1757–66.
16. Schmidt АС, Graf С, Brixius K, Scholze1 J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study. Clin Drug Investigat 2007; 27 (12): 841–9.
17. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215–25.
18. SENIORS, data on file. In: The Proceedings of the World Congress of Cardiology 2006.
2. Ройтберг Г.Е., Дорож Ж.В., Курукшина О.В. Роль адипокинов в прогрессировании метаболических нарушений у пациентов без ожирения с унсулинорезистентностью. Профилактическая медицина. 2010; 5: 23–6.
3. Boden-Albala B, Suzuki T, Hirata K et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J 2008; 156 (2): 405–10.
4. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86 (2): 713–8.
5. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–12.
6. Sharma AM, Pischon T, Hardt S et al. Hypothesis: beta-adrenergic receptor blockers and weight gain:systematic analysis. Hypertension 2001; 37: 250–4.
7. Elliot WJ, Meyer PM. Incident diabet s in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 207–10.
8 Kovacić D, Marinsek M, Gobec L et al. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008; 97 (1): 24–31.
9. Celik T, Iyisoy A et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24 (3): 591–6.
10. Wofford MR, Fnderson DC Jr, Brown CA et al. Antihypertenzive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001; 14: 694–8.
11. Schmieder RE, Gatzka C, Schachinger H et al. Obesity as a determinant for response to antihypertensive treatment. Br Med J 1993; 307: 537–40.
12. Ladage D, Brixius K, Hoyer H et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 2006; 33: 720–4.
13. Rizos E, Bairaktari E, Kostoula A et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8: 127–34.
14. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591–6.
15. Manrique C et al. Nebivolol improves insulin sensitivity in the TGR (Ren2) 27 rat. Metabolism 2011; 60 (12): 1757–66.
16. Schmidt АС, Graf С, Brixius K, Scholze1 J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study. Clin Drug Investigat 2007; 27 (12): 841–9.
17. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215–25.
18. SENIORS, data on file. In: The Proceedings of the World Congress of Cardiology 2006.
Авторы
Т.Е.Морозова, Е.Р.Латыйпова
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РФ
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.